AXNX insider transaction filings
Axonics, Inc. — 23 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-11-15. Screen AXNX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for AXNX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Axonics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-11-15 | 4 | Woock John — EVP, Chief Mktg/Strtgy Officer | Disposition to issuer (D): 77,403 @ $71 · Disposition to issuer (D): 13,125 (derivative) @ $0 · Disposition to issuer (D): 15,555 (derivative) @ $56.81 · Disposition to issuer (D): 3,581 (derivative) @ $45.18 | EDGAR |
| 2024-11-15 | 4 | snyderman nancy lynn MD — Director | Disposition to issuer (D): 14,944 @ $71 · Disposition to issuer (D): 4,167 (derivative) @ $36.90 · Disposition to issuer (D): 10,000 (derivative) @ $49.96 | EDGAR |
| 2024-11-15 | 4 | Sama Rinda — Chief Operating Officer | Disposition to issuer (D): 83,854 @ $71 · Disposition to issuer (D): 608 @ $71 · Disposition to issuer (D): 13,125 (derivative) @ $0 · Disposition to issuer (D): 11,019 (derivative) @ $56.81 · Disposition to issuer (D): 9,962 (derivative) @ $45.18 · Disposition to issuer (D): 6,294 (derivative) @ $69.37 | EDGAR |
| 2024-11-15 | 4 | Noblett Karen — Chief Medical Officer | Disposition to issuer (D): 34,428 @ $71 · Disposition to issuer (D): 7,500 (derivative) @ $0 · Disposition to issuer (D): 2,963 (derivative) @ $56.81 · Disposition to issuer (D): 6,348 (derivative) @ $45.18 · Disposition to issuer (D): 11,998 (derivative) @ $69.37 | EDGAR |
| 2024-11-15 | 4 | Lopez Esteban — Director | Disposition to issuer (D): 6,600 @ $71 · Disposition to issuer (D): 10,000 (derivative) @ $11.30 | EDGAR |
| 2024-11-15 | 4 | Keese Kari Leigh — Chief Financial Officer | Disposition to issuer (D): 40,362 @ $71 · Disposition to issuer (D): 3,125 (derivative) @ $0 | EDGAR |
| 2024-11-15 | 4 | Demski David M — Director | Disposition to issuer (D): 9,542 @ $71 · Disposition to issuer (D): 10,000 (derivative) @ $19.30 | EDGAR |
| 2024-11-15 | 4 | McNamara Robert — Director | Disposition to issuer (D): 14,861 @ $71 · Disposition to issuer (D): 10,000 (derivative) @ $36.90 · Disposition to issuer (D): 3,333 (derivative) @ $33.85 · Disposition to issuer (D): 5,000 (derivative) @ $56.20 | EDGAR |
| 2024-11-15 | 4 | Kiernan Jane E — Director | Disposition to issuer (D): 19,861 @ $71 | EDGAR |
| 2024-11-15 | 4 | Ford Alfred J Jr — Chief Commercial Officer | Disposition to issuer (D): 43,450 @ $71 · Disposition to issuer (D): 11,250 (derivative) @ $0 · Disposition to issuer (D): 4,655 (derivative) @ $45.18 | EDGAR |
| 2024-11-15 | 4 | COHEN RAYMOND W — Chief Executive Officer, Director | Disposition to issuer (D): 292,731 @ $71 · Disposition to issuer (D): 31,125 (derivative) @ $0 · Disposition to issuer (D): 196,451 (derivative) @ $56.81 · Disposition to issuer (D): 106,776 (derivative) @ $69.37 | EDGAR |
| 2024-11-15 | 4 | CARREL MICHAEL H — Director | Disposition to issuer (D): 17,861 @ $71 · Disposition to issuer (D): 5,000 (derivative) @ $36.90 · Disposition to issuer (D): 10,000 (derivative) @ $50.15 | EDGAR |
| 2024-11-12 | 4 | snyderman nancy lynn MD — Director | Gift (G): 5,000 @ $0 | EDGAR |
| 2024-10-03 | 4 | Keese Kari Leigh — Chief Financial Officer | Sale (S): 364 @ $69.40 · Sale (S): 2,597 @ $69.41 | EDGAR |
| 2024-07-25 | 4 | COHEN RAYMOND W — Chief Executive Officer, Director | Option exercise (M): 25,771 @ $14.19 · Option exercise (M): 78,125 @ $25.82 · Option exercise (M): 78,125 (derivative) @ $0 · Option exercise (M): 25,771 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Noblett Karen — Chief Medical Officer | Option exercise (M): 27,500 @ $0 · Sale (S): 11,288 @ $67.74 · Option exercise (M): 6,500 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Sama Rinda — Chief Operating Officer | Option exercise (M): 28,000 @ $0 · Option exercise (M): 10,500 (derivative) @ $0 · Option exercise (M): 17,500 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Woock John — EVP, Chief Mktg/Strtgy Officer | Option exercise (M): 28,000 @ $0 · Sale (S): 15,899 @ $67.74 · Option exercise (M): 10,500 (derivative) @ $0 · Option exercise (M): 17,500 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Keese Kari Leigh — Chief Financial Officer | Option exercise (M): 6,167 @ $0 · Sale (S): 3,489 @ $67.74 · Option exercise (M): 2,000 (derivative) @ $0 · Option exercise (M): 4,167 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Ford Alfred J Jr — Chief Commercial Officer | Option exercise (M): 25,500 @ $0 · Sale (S): 16,615 @ $67.74 · Option exercise (M): 10,500 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | COHEN RAYMOND W — Chief Executive Officer, Director | Option exercise (M): 63,400 @ $0 · Sale (S): 35,161 @ $67.74 · Option exercise (M): 21,900 (derivative) @ $0 · Option exercise (M): 41,500 (derivative) @ $0 | EDGAR |
| 2024-01-10 | 4 | Noblett Karen — Chief Medical Officer | Sale (S): 15,999 @ $69.00 | EDGAR |
| 2023-12-28 | 4 | Noblett Karen — Chief Medical Officer | Sale (S): 949 @ $63 · Sale (S): 7,051 @ $63.28 | EDGAR |
Recent 8-K events — Axonics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-11-15 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-01 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-04 | 8-K | 8.01 — Other Events | EDGAR |
| 2024-03-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-02-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-08 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AXNX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →